{"id":12300,"date":"2026-05-25T09:03:11","date_gmt":"2026-05-25T09:03:11","guid":{"rendered":"https:\/\/lemonn.co.in\/blog\/?p=12300"},"modified":"2026-05-25T09:03:13","modified_gmt":"2026-05-25T09:03:13","slug":"divis-laboratories-q4-fy26-results-dividend","status":"publish","type":"post","link":"https:\/\/lemonn.co.in\/blog\/market-updates\/divis-laboratories-q4-fy26-results-dividend\/","title":{"rendered":"Divi\u2019s Laboratories Q4 FY26 Results: Strong Profit Growth and \u20b930 Dividend Boost"},"content":{"rendered":"
\"Divi\u2019s<\/figure>\n\n\n

Divi\u2019s Laboratories reported a solid set of Q4 FY26 earnings, driven by steady demand in its pharmaceutical APIs and custom synthesis business. The company posted a 13% year-on-year rise in consolidated profit after tax (PAT) to \u20b9751 crore<\/strong>, compared to \u20b9662 crore in Q4 FY25. Revenue from operations also climbed nearly 10% YoY to \u20b92,831 crore.<\/p>\n\n\n\n

Along with the quarterly results, the pharma major announced a final dividend of \u20b930 per equity share<\/strong> for FY26, subject to shareholder approval at the upcoming AGM.<\/p>\n\n\n\n

Key Highlights of Divi\u2019s Laboratories Q4 FY26 Results<\/h2>\n\n\n\n
Metric<\/th>Q4 FY26<\/th>Q4 FY25<\/th>YoY Growth<\/th><\/tr><\/thead>
Revenue from Operations<\/td>\u20b92,831 crore<\/td>\u20b92,585 crore<\/td>9.5%<\/td><\/tr>
PAT<\/td>\u20b9751 crore<\/td>\u20b9662 crore<\/td>13.4%<\/td><\/tr>
EBITDA<\/td>\u20b9934 crore<\/td>\u20b9886 crore<\/td>5.4%<\/td><\/tr>
EBITDA Margin<\/td>33%<\/td>34.3%<\/td>Declined<\/td><\/tr>
Profit Before Tax<\/td>\u20b9963 crore<\/td>\u20b9864 crore<\/td>11.5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The company also reported a strong forex gain during the quarter, which supported overall profitability.<\/p>\n\n\n\n

Dividend Announcement<\/h2>\n\n\n\n

Divi\u2019s Laboratories recommended a final dividend of \u20b930 per equity share<\/strong> with a face value of \u20b92 each. This translates to a 1500% dividend payout<\/strong> for FY26.<\/p>\n\n\n\n

Important Dividend Dates<\/h3>\n\n\n\n
    \n
  • Record Date:<\/strong> July 24, 2026<\/li>\n\n\n\n
  • AGM Date:<\/strong> August 10, 2026<\/li>\n\n\n\n
  • Dividend payment will be made after shareholder approval at the AGM.<\/li>\n<\/ul>\n\n\n\n

    Full-Year FY26 Performance<\/h2>\n\n\n\n

    For the full financial year FY26, Divi\u2019s Laboratories delivered healthy growth across key financial metrics.<\/p>\n\n\n\n

    FY26 Financial Snapshot<\/h3>\n\n\n\n
    Metric<\/th>FY26<\/th>FY25<\/th>Growth<\/th><\/tr><\/thead>
    Revenue<\/td>\u20b910,560 crore+<\/td>\u20b99,300 crore+<\/td>13%<\/td><\/tr>
    PAT<\/td>\u20b92,568 crore<\/td>\u20b92,209 crore<\/td>17%<\/td><\/tr>
    EBITDA<\/td>\u20b93,948 crore<\/td>NA<\/td>Strong Growth<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    The company benefited from:<\/p>\n\n\n\n

      \n
    • Strong export demand<\/li>\n\n\n\n
    • Growth in custom synthesis business<\/li>\n\n\n\n
    • Stable operational execution<\/li>\n\n\n\n
    • Improved forex gains<\/li>\n<\/ul>\n\n\n\n

      EBITDA Margin Slightly Under Pressure<\/h2>\n\n\n\n

      Although revenue and profit improved, EBITDA margins slipped to 33% from 34.3%<\/strong> last year. The moderation was mainly linked to operational costs and business mix changes during the quarter.<\/p>\n\n\n\n

      Despite the margin pressure, Divi\u2019s Laboratories maintained strong profitability levels compared to peers in the pharmaceutical manufacturing sector.<\/p>\n\n\n\n

      Market Reaction and Share Price Outlook<\/h2>\n\n\n\n

      Investors reacted positively to the earnings announcement and dividend declaration. Analysts continue to remain optimistic on Divi\u2019s Laboratories due to:<\/p>\n\n\n\n

        \n
      • Strong balance sheet<\/li>\n\n\n\n
      • Consistent cash generation<\/li>\n\n\n\n
      • Leadership in API manufacturing<\/li>\n\n\n\n
      • Long-term CRDMO growth opportunities<\/li>\n<\/ul>\n\n\n\n

        Several brokerages expect the company to maintain healthy earnings momentum in FY27, especially if global pharmaceutical demand remains stable.<\/p>\n\n\n\n

        What\u2019s Driving Divi\u2019s Laboratories Growth?<\/h2>\n\n\n\n

        Divi\u2019s Laboratories continues to benefit from:<\/p>\n\n\n\n

          \n
        • Increasing demand for generic APIs<\/li>\n\n\n\n
        • Expansion in custom synthesis projects<\/li>\n\n\n\n
        • Strong global customer relationships<\/li>\n\n\n\n
        • Manufacturing scale advantages<\/li>\n<\/ul>\n\n\n\n

          The company\u2019s focus on operational efficiency and export-driven growth has helped it remain one of India\u2019s strongest pharma manufacturing companies.<\/p>\n\n\n\n

          Conclusion<\/h2>\n\n\n\n

          Divi\u2019s Laboratories delivered another steady quarter with double-digit profit growth and healthy revenue expansion. The company\u2019s Q4 FY26 PAT of \u20b9751 crore<\/strong>, combined with a generous \u20b930 final dividend<\/strong>, reflects management confidence and strong financial health.<\/p>\n\n\n\n

          While EBITDA margins saw a slight dip, Divi\u2019s Laboratories remains well-positioned for long-term growth in the global pharmaceutical and API market.<\/p>\n\n\n\n

          FAQs<\/h2>\n\n\n
          \n
          \n
          \n

          Q. What was Divi\u2019s Laboratories Q4 FY26 PAT?<\/h3>\n
          \n\n

          Divi\u2019s Laboratories reported a consolidated PAT of \u20b9751 crore in Q4 FY26, up 13% YoY.<\/p>\n\n<\/div>\n<\/div>\n

          \n

          Q. How much dividend did Divi\u2019s Laboratories announce?<\/h3>\n
          \n\n

          The company announced a final dividend of \u20b930 per equity share for FY26.<\/p>\n\n<\/div>\n<\/div>\n

          \n

          Q. What was Divi\u2019s Laboratories Q4 FY26 revenue?<\/h3>\n
          \n\n

          Revenue from operations stood at \u20b92,831 crore during the quarter.<\/p>\n\n<\/div>\n<\/div>\n

          \n

          Q. What is the dividend record date?<\/h3>\n
          \n\n

          The dividend record date is July 24, 2026.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

          Divi\u2019s Laboratories reported a solid set of Q4 FY26 earnings, driven by steady demand in its pharmaceutical APIs and custom synthesis business. The company posted a 13% year-on-year rise in consolidated profit after tax (PAT) to \u20b9751 crore, compared to \u20b9662 crore in Q4 FY25. Revenue from operations also climbed nearly 10% YoY to \u20b92,831 […]<\/p>\n","protected":false},"author":3,"featured_media":12301,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","_ayudawp_aiss_exclude":false,"_ayudawp_aiss_summary":"Divi\u2019s Laboratories reported a solid set of Q4 FY26 earnings, driven by steady demand in its pharmaceutical APIs and custom synthesis business. For the full financial year FY26, Divi\u2019s Laboratories delivered healthy growth across key financial metrics. Divi\u2019s Laboratories reported a consolidated PAT of \u20b9751 crore in Q4 FY26, up 13% YoY.","_ayudawp_aiss_summary_provider":"extractive","_ayudawp_aiss_summary_hash":"a876b23f4465e7438a119a6016444b20496e90b7","footnotes":""},"categories":[512],"tags":[],"class_list":["post-12300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-updates"],"blocksy_meta":[],"uagb_featured_image_src":{"full":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results.png",890,593,false],"thumbnail":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results-150x150.png",150,150,true],"medium":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results-300x200.png",300,200,true],"medium_large":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results-768x512.png",768,512,true],"large":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results.png",890,593,false],"1536x1536":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results.png",890,593,false],"2048x2048":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results.png",890,593,false],"web-stories-poster-portrait":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results-640x593.png",640,593,true],"web-stories-publisher-logo":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results-96x96.png",96,96,true],"web-stories-thumbnail":["https:\/\/lemonn.co.in\/blog\/wp-content\/uploads\/2026\/05\/Divis-Laboratories-Q4-FY26-Results-150x100.png",150,100,true]},"uagb_author_info":{"display_name":"Team Lemonn","author_link":"https:\/\/lemonn.co.in\/blog\/author\/ashu\/"},"uagb_comment_info":0,"uagb_excerpt":"Divi\u2019s Laboratories reported a solid set of Q4 FY26 earnings, driven by steady demand in its pharmaceutical APIs and custom synthesis business. The company posted a 13% year-on-year rise in consolidated profit after tax (PAT) to \u20b9751 crore, compared to \u20b9662 crore in Q4 FY25. Revenue from operations also climbed nearly 10% YoY to \u20b92,831…","_links":{"self":[{"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/posts\/12300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/comments?post=12300"}],"version-history":[{"count":1,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/posts\/12300\/revisions"}],"predecessor-version":[{"id":12302,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/posts\/12300\/revisions\/12302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/media\/12301"}],"wp:attachment":[{"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/media?parent=12300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/categories?post=12300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lemonn.co.in\/blog\/wp-json\/wp\/v2\/tags?post=12300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}